Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Friday announced the launch of AstraZeneca Direct, an online platform designed to provide eligible US patients with a simple, convenient way to access prescribed medications at a transparent cash price with home delivery.

The service targets patients with chronic conditions, including asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection.

From October, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapagliflozin) can purchase these medications directly through the platform for up to 70% off the list price. FLUMIST (Influenza Vaccine Live, Intranasal) will also be available for home delivery.

Joris Silon, US country president at AstraZeneca, said that the platform complements AstraZeneca's existing patient support programmes and provides transparent pricing and convenient access.

The platform will be accessible at AstraZenecaDirect.com starting 1 October 2025.